In a recent study, Chang et al. demonstrated that exosomes in the serums of patients with PDAC harbouring KRAS mutations were carrying high amounts of survivin, as did KRAS-transformed fibroblasts and pancreatic cancer cells [47]. This evidence concerns the gene BIRC5 and pancreatic neoplasm.